Articles tagged "Co-stimulation"

2020 American Transplant Congress
Two Pilot Studies Exploring the Diagnostic and Predictive Potential of Serum LAG3 and FGL1 in Kidney Transplant Recipients
Y. Li¹, L. Yan¹, Y. Li¹, C. Yang¹, Z. Wan¹, Y. An¹, Y. Bai¹, L. Wang¹, Y. Shi²
¹Department of Laboratory Medicine, West China Hospital, Chengdu, China, ²Department of Nephrology, West China Hospital, Chengdu, China
*Purpose: Lymphocyte activation gene 3 (LAG3), an immune checkpoint, plays an important role in the negative regulation of immune response and the induction of immune…
2020 American Transplant Congress
Belatacept Provides Superior Inhibition of Donor Specific Antibody Formation in Kidney Transplant Recipients with Acute Rejection
O. Cristea, C. Larsen, I. Badell
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: The factors responsible for chronic renal allograft dysfunction and premature graft loss are incompletely understood and likely multifactorial. Immunologic injury partially attributable to the…
2020 American Transplant Congress
Belatacept Combined with BTLA Prolong Allogeneic Kidney Graft Survival and Inhibited Acute Rejection after Kidney Transplantation
H. Zhang, Z. Wang, J. Zhang, Z. Han, J. Tao, H. Chen, L. Sun, R. Tan, M. Gu
Jiangsu Province Hospital, Nanjing, China
*Purpose: Belatacept as a high-affinity variant of CTLA-4Ig, has been applied into kidney transplantation to against acute rejection. However, adoption of Belatacept has been limited…
2020 American Transplant Congress
Naïve B Cells Regulation by TLR-Breg Cells In Vitro
Q. Fu, K. Lee, G. Huai, K. Deng, N. J. Feeney, C. Leguern, S. Deng, J. F. Markmann
Center for Transplant Science, MGH, Boston, MA
*Purpose: Regulatory B cells (Bregs) have shown great potential in cell therapies for murine organ transplantation by inhibiting the proliferation of cytotoxic and helper T…
2020 American Transplant Congress
Costimulatory Signal Impacts Car Treg Fate and Function in Transplantation
B. Lamarthée¹, A. Marchal¹, S. Charbonnier¹, T. Blein¹, K. Vogt², M. Titeux¹, N. Pallet³, M. Delville¹, E. Six¹, D. Anglicheau⁴, C. Legendre⁴, B. Sawitzki², J. Taupin⁵, M. Cavazzana¹, I. André¹, J. Zuber¹
¹Inserm U1163, Institut Imagine, Paris, France, ²Department of Immunology, Charité University Hospital, Berlin, Germany, ³Inserm U1147, Centre Universitaire des Saints Pères, Paris, France, ⁴Service de Transplantation Rénale Adulte, Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Paris, France, ⁵Inserm U1160, Centre Hayem, Paris, France
*Purpose: Donor-specific regulatory T-cell (Treg) therapy has emerged as a potent strategy to promote immune tolerance in experimental transplantation. However, a major stumbling block in…
2020 American Transplant Congress
Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation
T. L. Shertel¹, M. A. Wynd¹, M. A. Pereiras¹, J. T. McKeen¹, Y. Y. Yushkov², B. R. Schleich³, S. E. Geatrakas², A. Patel², M. J. Goldstein²
¹Pharmacy, Hackensack University Medical Center, Hackensack, NJ, ²Organ Transplant, Hackensack University Medical Center, Hackensack, NJ, ³Patient Safety and Quality, Hackensack University Medical Center, Hackensack, NJ
*Purpose: Our center created an immunosuppression protocol using de novo belatacept (DNB) in the setting of lymphocyte depletion to increase the utilization of deceased donor…
2020 American Transplant Congress
Targeting the CD40/CD40L Axis in Sensitized Nonhuman Primate Allotransplantation
Z. W. Fitch, R. Schmitz, M. Manook, A. Y. Choi, J. Yoon, J. Kwun, S. J. Knechtle
Duke University, Durham, NC
*Purpose: Blockade of the CD28/B7 costimulation pathway has shown great promise as part of desensitization and maintenance immunosuppression regimens in our sensitized nonhuman primate model.…
2020 American Transplant Congress
Novel Treatment of Acute Antibody-Mediated Rejection in a Nonhuman Primate Model of Kidney Allotransplantation
R. Schmitz¹, Z. W. Fitch¹, A. Y. Choi¹, M. Manook¹, J. Yoon¹, J. D. Lambris², J. Kwun¹, S. J. Knechtle¹
¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience acute antibody mediated rejection (AMR) with limited treatment options. We tested a novel treatment strategy for…
2020 American Transplant Congress
Maintenance Belatacept Therapy is Associated with Increased Rates of Polyoma Viremia
D. Conti, E. Maciera, D. Pluckrose, M. Garner, D. Schuster, S. Patel
Albany Medical Center, Albany, NY
*Purpose: The introduction of belatacept costimulatory blockade therapy has added a novel and powerful agent to the immunosuppressive armamentarium utilized after renal transplantation. However, limited…
2020 American Transplant Congress
Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients: Rejection Risk, Prevention and Transcriptional Signature in Allograft
N. Murakami¹, G. Reid², A. Weins¹, B. Adam², M. Mengel², L. Riella¹
¹Brigham and Women's Hospital, Boston, MA, ²University of Alberta, Edmonton, AB, Canada
*Purpose: Immune checkpoint inhibitor (ICI) use has changed the landscape of cancer treatment. Several cases of acute rejection in use of ICI have been reported,…

« Previous Page
1
…
5
6
7
8
9
…
30
Next Page »